

Disclosures

Personal Commercial (5)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|----------------|--|--------------------------|---------------------|
| <i>Self</i> | | | |
| Arineta | Consultant Fees/Honoraria | None (\$0) | General Cardiology |
| Cleerly | Ownership Interest/Partnership/Principal | Significant (>= \$5,000) | Noninvasive Imaging |
| Cleerly | Salary | Significant (>= \$5,000) | General Cardiology |
| Cleerly | Ownership Interest/Partnership/Principal | None (\$0) | General Cardiology |
| Tourmaline Bio | Consultant Fees/Honoraria | Modest (< \$5,000) | Other |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (6)

| Non-Commercial Entity Name | Relationship Category | Compensation Level | Topic Area(s) |
|----------------------------|--|--------------------------|---------------------|
| <i>Self</i> | | | |
| GE Healthcare | Research/Research Grants ‡ DISCOVER-VP | Significant (>= \$5,000) | General Cardiology |
| NIH/NHLBI | Research/Research Grants ‡ Computerized Visualization and Prediction of Coronary Artery Ischemia | Significant (>= \$5,000) | General Cardiology |
| NIH/NHLBI | Research/Research Grants ‡ U01 HL105907: The primary aim of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches, or ISCHEMIA trial | Significant (>= \$5,000) | Noninvasive Imaging |
| NIH/NHLBI | Research/Research Grants ‡ R01 HL118019: Anatomic and Physiologic Determinants of Vessel-Specific Ischemia by Coronary CT | Significant (>= \$5,000) | Noninvasive Imaging |
| NIH/NHLBI | Research/Research Grants ‡ R01 HL115150: Gender-Specific Coronary Plaque Characteristics and Risk of Myocardial Infarction | Significant (>= \$5,000) | Noninvasive Imaging |
| NIH/NHLBI | Research/Research Grants ‡ R01 HL111141: Dual Energy Computed Tomography for Determining Coronary Lesion-Specific Ischemia | Significant (>= \$5,000) | Noninvasive Imaging |

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/27/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/27/2024
URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 9/27/2024
URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 9/27/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.